Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroko Otsuka

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Breast Cancer (Tokyo, Japan)|July 6, 2013
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancerHiroko Otsuka, Teruhiko Fujii, Uhi Toh, et al.
Journal of Clinical Pathology|April 1, 2016
Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytesMichi Morita, Rin Yamaguchi, Maki Tanaka, et al.
Biochemical and Biophysical Research Communications|September 28, 2014
Aralin, a type II ribosome-inactivating protein from Aralia elata, exhibits selective anticancer activity through the processed form of a 110-kDa high-density lipoprotein-binding protein: a promising anticancer drugHiroko Otsuka, Yoshitaka Gotoh, Takashi Komeno, et al.
Medical Molecular Morphology|March 27, 2010
Pleomorphic carcinoma of the breast in a 17-year-old womanRin Yamaguchi, Maki Tanaka, Miki Yamaguchi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 16, 2021
Proteomic and phospholipidomic characterization of extracellular vesicles inducing tumor microenvironment in Epstein-Barr virus-associated lymphomasMasatoshi Ito, Kai Kudo, Hiroshi Higuchi, et al.
The Kurume Medical Journal|January 19, 2012
Giant malignant phyllodes tumor: a case reportMiki Takenaka, Uhi Toh, Hiroko Otsuka, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 9, 2023
Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleusShintaro Nakamura, Yasutaka Miyachi, Akihito Shinjo, et al.
The Biochemical Journal|January 20, 2022
Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic miceHiroko Otsuka, Hisashi Yokomizo, Shintaro Nakamura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 28, 2019
[Endoscopic Submucosal Dissection(ESD)as a "Loco-Regional Cancer Therapy" for Colorectal Tumors]Rieko Shimojima, Hiroko Otsuka, Kimiko Kihara, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy]Hiroki Takahashi, Teruhiko Fujii, Yuka Inoue, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Breast Cancer (Tokyo, Japan)|July 6, 2013
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancerHiroko Otsuka, Teruhiko Fujii, Uhi Toh, et al.
Journal of Clinical Pathology|April 1, 2016
Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytesMichi Morita, Rin Yamaguchi, Maki Tanaka, et al.
Biochemical and Biophysical Research Communications|September 28, 2014
Aralin, a type II ribosome-inactivating protein from Aralia elata, exhibits selective anticancer activity through the processed form of a 110-kDa high-density lipoprotein-binding protein: a promising anticancer drugHiroko Otsuka, Yoshitaka Gotoh, Takashi Komeno, et al.
Medical Molecular Morphology|March 27, 2010
Pleomorphic carcinoma of the breast in a 17-year-old womanRin Yamaguchi, Maki Tanaka, Miki Yamaguchi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 16, 2021
Proteomic and phospholipidomic characterization of extracellular vesicles inducing tumor microenvironment in Epstein-Barr virus-associated lymphomasMasatoshi Ito, Kai Kudo, Hiroshi Higuchi, et al.
The Kurume Medical Journal|January 19, 2012
Giant malignant phyllodes tumor: a case reportMiki Takenaka, Uhi Toh, Hiroko Otsuka, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 9, 2023
Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleusShintaro Nakamura, Yasutaka Miyachi, Akihito Shinjo, et al.
The Biochemical Journal|January 20, 2022
Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic miceHiroko Otsuka, Hisashi Yokomizo, Shintaro Nakamura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 28, 2019
[Endoscopic Submucosal Dissection(ESD)as a "Loco-Regional Cancer Therapy" for Colorectal Tumors]Rieko Shimojima, Hiroko Otsuka, Kimiko Kihara, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy]Hiroki Takahashi, Teruhiko Fujii, Yuka Inoue, et al.
Pageof 3